Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 37Prostatic Neoplasms 30Multiple Myeloma 30Colorectal Neoplasms 27Pancreatic Neoplasms 26Melanoma 23Carcinoma, Renal Cell 23Ovarian Neoplasms 21Lymphoma 20Burkitt Lymphoma 19Triple Negative Breast Neoplasms 18Myelodysplastic Syndromes 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Urinary Bladder Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Fallopian Tube Neoplasms 14Carcinoma, Hepatocellular 14Oropharyngeal Neoplasms 13Glioma 13Sarcoma 12Mouth Neoplasms 12Carcinoma 12Astrocytoma 12

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Specimen Handling × 90 days × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡